Why did Goldman Sachs upgrade BioNTech stock?

Goldman Sachs upgraded BioNTech due to its expanding footprint in oncology and antibody-drug conjugates, positioning it for future growth.

What is BioNTech's new price target?

The new 12-month price target for BioNTech set by Goldman Sachs is $142.

Will BioNTech's oncology pipeline drive its stock?

Yes, analysts believe BioNTech's oncology pipeline is set to become a more significant driver of stock performance than its COVID-19 business.

Home / Business and Economy / BioNTech: Oncology Prowess to Eclipse COVID-19?

BioNTech: Oncology Prowess to Eclipse COVID-19?

19 Jan

•

Summary

Goldman Sachs upgrades BioNTech to Buy with a $142 target.
Analyst highlights BioNTech's expanding oncology and ADC footprint.
Oncology pipeline expected to drive future stock performance.

BioNTech: Oncology Prowess to Eclipse COVID-19?

Goldman Sachs analyst Asad Haider has upgraded BioNTech (NASDAQ:BNTX) to a Buy rating, setting a 12-month price target of $142, which suggests a 30% increase from current levels. Haider's bullish outlook stems from BioNTech's strategic positioning in next-generation immuno-oncology and antibody-drug conjugates (ADCs).

The analyst emphasizes that BioNTech's potential lies beyond its COVID-19 vaccine legacy. The company boasts a diversified oncology portfolio, including novel bispecifics and mRNA-based cancer vaccines. This broad approach is expected to reduce dependence on any single trial outcome and drive future value.